Special Reports in Personalized Cancer Care | Specialty

Goy Taps Into the True Potential of Precision Medicine in Oncology

September 18th 2021

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Pushing the Boundaries of Personalized Cancer Care

August 21st 2021

When imagining a champion of change, one can easily point to Laura J. van ’t Veer, PhD, the 2020 Giants of Cancer Care® award winner in Cancer Diagnostics, as a prime example.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 11th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

June 5th 2020

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Analysis Highlights Acquired Resistance Mechanisms in METex14+ NSCLC

June 5th 2020

Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

June 5th 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Review Reveals Challenges of NGS Testing in Community Practices, Proactive Measures to Increase Utility

June 3rd 2020

Jennifer Marie Suga, MD, discusses the importance of understanding the current limitations to next-generation sequencing in oncology, the impact of the study findings, and remaining challenges regarding NGS testing in the community setting.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

June 2nd 2020

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Systematic Review Spotlights Potential Markers for ctDNA Use in CRC

June 2nd 2020

Sander Bach, discusses the rationale for conducting this systematic review in CRC, key inclusion/exclusion criteria, and the potential clinical implications of these findings.

EU Panel Backs Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

June 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non–small cell lung cancer not previously treated with ROS1 inhibitors.

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

June 1st 2020

RET inhibitor pralsetinib induced responses in a number of patients with rare and difficult to treat RET fusion–positive solid tumors.

IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer

May 28th 2020

The rate of global molecular testing is low and is limited by a number of factors, including cost, quality, turn-around time, access, and lack of awareness of testing.

Dr. Dimou on Managing Disease Progression in NSCLC

May 22nd 2020

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved two companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with olaparib.

FDA Approves PD-L1 IHC 28-8 pharmDx as Companion Diagnostic for Nivolumab Plus Ipilimumab in NSCLC

May 18th 2020

The FDA has approved PD-L1 IHC 28-8 pharmDx for use as a companion diagnostic to identify patients with metastatic non–small cell lung cancer with PD-L1 tumor expression ≥1%, making them eligible for frontline treatment with nivolumab plus ipilimumab.

Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

May 18th 2020

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Larotrectinib Benefits Patients With NTRK Fusions, Regardless of Pretreatment or Performance Status

May 11th 2020

David S. Hong, MD, discusses the results of these analyses with larotrectinib in patients with NTRK alterations.

FDA Approves myChoice CDx as Companion Diagnostic for Olaparib in Ovarian Cancer

May 11th 2020

The FDA has approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with positive homologous recombination deficiency status, making them eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.